The themes Danaher is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Die Umsatzanteile sind Schätzungen für six months ended June 26, 2026 und keine Zahlen aus einem eingereichten Bericht.
Cytiva bioprocessing products
Filters, resins, liquids, single-use equipment, and services that drugmakers use to develop and manufacture biological medicines.
Pall filtration products
Filters and related equipment that remove contaminants from liquids and gases used in medicine, research, food production, electronics manufacturing, and other industries.
Biacore 8S
A Cytiva instrument that lets researchers test how potential drug molecules interact with their targets.
SCIEX mass spectrometers
Instruments that identify and measure molecules in samples, used in drug research, clinical testing, and food and environmental testing.
Beckman Coulter clinical testing systems
Laboratory instruments, tests, and software that analyze blood and other body samples to help diagnose and monitor health conditions.
Cepheid GeneXpert tests
Systems and tests that detect genetic material from organisms or diseases, including tests used in hospitals and other care settings.
Danaher owns more than 15 operating companies grouped into biotechnology, life sciences, and diagnostics. Their products help researchers study cells and other biological material, help drugmakers make biological medicines, and help healthcare workers test samples and monitor patients. Many products are used up or replaced regularly, so customers buy supplies as well as instruments and services.
Gebaut aus den eigenen Einreichungen von Danaher Corp. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
232,14 $-1,3 %Schluss 12. Nov.
Zahlen bis 25. September 2026, aus dem 10-Q vom 21. Oktober 2026
Danaher sells instruments, supplies, and services used in biological research, drug manufacturing, and medical testing.
Grade B+
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 40 Quartalen der Notenhistorie von Danaher Corp.. Die übrigen 38 reichen zurück bis Februar 2017.